124 related articles for article (PubMed ID: 35081358)
1. Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2.
Zhao H; Lu J; Yan T; Han F; Sun J; Yin X; Chen L; Shen C; Wunderlich M; Yun W; Yang L; Chen L; Su D; Bohlander SK; Wang F; Mulloy JC; Li C; Chen J; Huang H; Jiang X
Cell Rep; 2022 Jan; 38(4):110253. PubMed ID: 35081358
[TBL] [Abstract][Full Text] [Related]
2. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
[TBL] [Abstract][Full Text] [Related]
3. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
Lyu Y; Lou J; Yang Y; Feng J; Hao Y; Huang S; Yin L; Xu J; Huang D; Ma B; Zou D; Wang Y; Zhang Y; Zhang B; Chen P; Yu K; Lam EW; Wang X; Liu Q; Yan J; Jin B
Leukemia; 2017 Dec; 31(12):2543-2551. PubMed ID: 28400619
[TBL] [Abstract][Full Text] [Related]
4. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.
Pan X; Chang Y; Ruan G; Zhou S; Jiang H; Jiang Q; Huang X; Zhao XS
Clin Exp Med; 2024 Feb; 24(1):35. PubMed ID: 38349460
[TBL] [Abstract][Full Text] [Related]
5. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal.
Li Y; Xue M; Deng X; Dong L; Nguyen LXT; Ren L; Han L; Li C; Xue J; Zhao Z; Li W; Qing Y; Shen C; Tan B; Chen Z; Leung K; Wang K; Swaminathan S; Li L; Wunderlich M; Mulloy JC; Li X; Chen H; Zhang B; Horne D; Rosen ST; Marcucci G; Xu M; Li Z; Wei M; Tian J; Shen B; Su R; Chen J
Cell Stem Cell; 2023 Aug; 30(8):1072-1090.e10. PubMed ID: 37541212
[TBL] [Abstract][Full Text] [Related]
6. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
7. Notch pathway activation targets AML-initiating cell homeostasis and differentiation.
Lobry C; Ntziachristos P; Ndiaye-Lobry D; Oh P; Cimmino L; Zhu N; Araldi E; Hu W; Freund J; Abdel-Wahab O; Ibrahim S; Skokos D; Armstrong SA; Levine RL; Park CY; Aifantis I
J Exp Med; 2013 Feb; 210(2):301-19. PubMed ID: 23359070
[TBL] [Abstract][Full Text] [Related]
8. Compound C induces autophagy and apoptosis in parental and hydroquinone-selected malignant leukemia cells through the ROS/p38 MAPK/AMPK/TET2/FOXP3 axis.
Chiou JT; Huang CH; Lee YC; Wang LJ; Shi YJ; Chen YJ; Chang LS
Cell Biol Toxicol; 2020 Aug; 36(4):315-331. PubMed ID: 31900833
[TBL] [Abstract][Full Text] [Related]
9. ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia.
Demajo S; Uribesalgo I; Gutiérrez A; Ballaré C; Capdevila S; Roth M; Zuber J; Martín-Caballero J; Di Croce L
Oncogene; 2014 Nov; 33(48):5501-10. PubMed ID: 24292673
[TBL] [Abstract][Full Text] [Related]
10. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
[TBL] [Abstract][Full Text] [Related]
11. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
[TBL] [Abstract][Full Text] [Related]
12. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
13. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
15. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
16. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
17. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
18. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia.
Liu J; Min S; Kim D; Park J; Park E; Pei S; Koh Y; Shin DY; Byun JM; Ko M; Yoon SS; Hong J
Leukemia; 2023 Aug; 37(8):1638-1648. PubMed ID: 37393342
[TBL] [Abstract][Full Text] [Related]
20. Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine.
Shao J; Shah S; Ganguly S; Zu Y; He C; Li Z
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
